| Subject: | FDA MedWatch-Cubicin (daptomycin for injection)- Potentially Significant Impurity Isolated From Reconstituted Product Stored In ReadyMED Pumps |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 9 Apr 2008 - 02:00 pm |
| Audience: Infectious disease healthcare professionals, hospital risk managers, and nursing service managers Cubist Pharmaceuticals, Inc. had informed healthcare professionals that a potentially significant impurity, 2-mercaptobenzothiazole (MBT), has been isolated from reconstituted Cubicin (daptomycin for injection) stored in ReadyMED elastomeric infusion pumps manufactured by Cardinal Health, Inc. MBT is used in the manufacture of rubber and has been reported to leach from rubber stoppers and... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
